Abstract
Current research suggests that amygdalar volumes in patients with Alzheimer’s disease (AD) may be a relevant measure for its early diagnosis. However, findings are still inconclusive and controversial, partly because studies did not focus on the earliest stage of the disease. In this study, we measured amygdalar atrophy in 48 AD patients and 82 healthy controls (HC) by using a multi-atlas procedure, MAPER. Both hippocampal and amygdalar volumes, normalized by intracranial volume, were significantly reduced in AD compared with HC. The volume loss in the two structures was of similar magnitude (~24%). Amygdalar volume loss in AD predicted memory impairment after we controlled for age, gender, education, and, more important, hippocampal volume, indicating that memory decline correlates with amygdalar atrophy over and above hippocampal atrophy. Amygdalar volume may thus be as useful as hippocampal volume for the diagnosis of early AD. In addition, it could be an independent marker of cognitive decline. The role of the amygdala in AD should be reconsidered to guide further research and clinical practice.
Keywords: Automatic segmentation, brain, hippocampus, MRI, neuropsychology.
Current Alzheimer Research
Title:Amygdalar Atrophy in Early Alzheimer’s Disease
Volume: 11 Issue: 3
Author(s): Yanica Klein-Koerkamp, Rolf A. Heckemann, Kylee T. Ramdeen, Olivier Moreaud, Sandrine Keignart, Alexandre Krainik, Alexander Hammers, Monica Baciu, Pascal Hot and for the Alzheimer’s Disease Neuroimaging Initiative
Affiliation:
Keywords: Automatic segmentation, brain, hippocampus, MRI, neuropsychology.
Abstract: Current research suggests that amygdalar volumes in patients with Alzheimer’s disease (AD) may be a relevant measure for its early diagnosis. However, findings are still inconclusive and controversial, partly because studies did not focus on the earliest stage of the disease. In this study, we measured amygdalar atrophy in 48 AD patients and 82 healthy controls (HC) by using a multi-atlas procedure, MAPER. Both hippocampal and amygdalar volumes, normalized by intracranial volume, were significantly reduced in AD compared with HC. The volume loss in the two structures was of similar magnitude (~24%). Amygdalar volume loss in AD predicted memory impairment after we controlled for age, gender, education, and, more important, hippocampal volume, indicating that memory decline correlates with amygdalar atrophy over and above hippocampal atrophy. Amygdalar volume may thus be as useful as hippocampal volume for the diagnosis of early AD. In addition, it could be an independent marker of cognitive decline. The role of the amygdala in AD should be reconsidered to guide further research and clinical practice.
Export Options
About this article
Cite this article as:
Klein-Koerkamp Yanica, Heckemann A. Rolf, Ramdeen T. Kylee, Moreaud Olivier, Keignart Sandrine, Krainik Alexandre, Hammers Alexander, Baciu Monica, Hot Pascal and Disease Neuroimaging Initiative Alzheimer’s for the, Amygdalar Atrophy in Early Alzheimer’s Disease, Current Alzheimer Research 2014; 11 (3) . https://dx.doi.org/10.2174/1567205011666140131123653
DOI https://dx.doi.org/10.2174/1567205011666140131123653 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DHODH Hot Spots: An Underexplored Source to Guide Drug Development Efforts
Current Topics in Medicinal Chemistry Marine Sponges: Potential Sources of New Antimicrobial Drugs
Current Pharmaceutical Biotechnology Isolation of Antibodies From Non-Human Primates for Clinical Use
Current Drug Discovery Technologies Physiological Proteins in Therapeutics: A Current Review on Interferons
Mini-Reviews in Medicinal Chemistry Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews Non-IgE Mediated Food Allergy – Update of Recent Progress in Mucosal Immunity
Inflammation & Allergy - Drug Targets (Discontinued) Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews Withdrawal Notice: Review on Dengue Virus Fusion/Entry Process and Their Inhibition by Small Bioactive Molecules
Mini-Reviews in Medicinal Chemistry New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors
Infectious Disorders - Drug Targets Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Recent Development and Future Prospects of Plant-Based Vaccines
Current Drug Metabolism Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets The Role of Microglial Cells on Neuroinflammation: Possible Therapeutic Applications
Recent Patents on Regenerative Medicine Recent Patents on Alphavirus Protein Expression and Vector Production
Recent Patents on Biotechnology